INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors.

Eric Angevin,Mary S. Barnette,Todd Michael Bauer,Daniel C Cho,Catherine E. Ellis,Hui K. Gan,Aaron Richard Hansen,Axel Hoos,Roxanne C. Jewell,Jessica Katz,Juan Martin-Liberal,Michele Maio,Patrick Mayes,Michael Millward,Victor Moreno,Anthony J. Olszanski,Danny Rischin,Jan H. M. Schellens,Sapna Yadavilli,Helen Zhou

INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors.

2017

TPS3113Background: Inducible T cell Co-Stimulator (ICOS), a member of the CD28/B7/CTLA-4 receptor superfamily expressed on T cells after engagement with cognate antigen and activation, provides a c...

Keywords:

Antibody
Pathology
Agonist
Pembrolizumab
Cancer research
Medicine
Receptor
CD28
T cell
open label study
Antigen

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations